Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shree Ganesh Remedies Limited has published its unaudited standalone and consolidated financial results for the quarter ended June 30, 2025 in the newspaper, as required by SEBI regulations. Consolidated revenue from operations stood at ₹2,466.79 lakhs, largely flat compared to ₹2,477.99 lakhs in the same quarter last year but slightly up from ₹2,443.19 lakhs in the previous quarter (Q4 FY25). Net profit after tax fell to ₹344.51 lakhs, a significant drop from ₹659.00 lakhs in Q4 FY25 and ₹464.88 lakhs in Q1 FY25. EPS for the quarter came in at ₹2.68, down from ₹3.62 a year ago. On a standalone basis, EBITDA was ₹795.83 lakhs with an EBITDA margin of 31.42%, compared to 34.23% in the year-ago quarter. The results were approved by the Board on August 1, 2025.
Profitability has weakened sharply both quarter-on-quarter and year-on-year despite steady revenues, indicating margin pressure for shareholders. The stock may face short-term negativity due to the earnings decline, though revenue stability suggests the underlying business remains intact.